Abstract:Abstract Objective: Diffuse large B cell lymphoma (DLBCL) is the most common subtype of non-Hodgkin lymphoma world wide. It is a phenotypically and genetically heterogeneous disease, accounting for 30-40% of all cases. 50%-70% of patients can be cured by the R-CHOP regimen, but nearly one-third of patients develop relapsed or refractory disease. CC chemokine receptor 2 (CCR2), the high affinity receptor of CC-Chemokine Ligand 2 (CCL2), which is the most representative of the CC chemokine family members, has be regarded to involve in tumor growth, angiogenesis, epithelial mesenchymal transition, metastasis and immune escape etc.. In recent years, the role and mechanism in DLBCL has not been reported yet. Our preliminary study showed that high expression of CCR2 was correlated with clinicopathological characteristics, and an adverse prognostic factor for overall survival (OS) and progression-free survival (PFS) of DLBCL patients. The purpose of this study is to investigate the role of CCR2 expression in DLBCL cells proliferation and migration by in vitro and in vivo. Methods: CCR2 expression were analyzed in human DLBCL cell lines (SUDHL-2, SUDHL-4, SUDHL-6, OCI-Ly8 and OCI-Ly10) by Western blot (WB). SUDHL-2 and OCI-Ly8 cells were incubated with CCR2 antagonist SC-202525 (Santa Crutz Biotechnology), and control cells were left untreated. The proliferation, migration, apoptosis and signaling pathway were detected by CCK8, transwell, flow cytometry (FC) and WB, respectively in vitro. The engraftment, tumor growth, dissemination and survival time were observed in BALB/c nude mice. Results: CCR2 were expressed in all human DLBCL cell lines (relative CCR2 expression was higher in SUDHL-2, SUDHL-4 and OCI-Ly8 than in SUDHL-6 and OCI-Ly10 cell lines). Blockade of CCR2 expression signaling with CCR2 antagonist inhibited tumor cell proliferation, migration and anti-apoptosis ability. The signaling involved in the proliferation and migration of DLBCL cells by activating PI3K/Akt signaling pathway, and induced apoptosis through activation of P38MARK signaling pathway. Expression of CCR2 was also associated with increased engraftment, tumor growth and dissemination, and decreased survival time in xenograft mice. Furthermore, administration of CCR2 antagonist decreased tumor growth and dissemination of DLBCL cells, and increased survival time in the xenograft model. Conclusions: Our study demonstrates that CCR2 plays an important role in the development of DLBCL by stimulating cell proliferation, migration and anti-apoptosis. The inhibition of CCR2 may, therefore, be a potential target for anticancer therapy in DLBCL. Disclosures No relevant conflicts of interest to declare.

The Human Chemokine Receptor CCRL2 Suppresses Chemotaxis and Invasion by Blocking CCL2-induced Phosphorylation of P38 MAPK in Human Breast Cancer Cells

CC chemokine receptor-like 1 functions as a tumour suppressor by impairing CCR7-related chemotaxis in hepatocellular carcinoma.

CCR2 Expression Promotes Diffuse Large B Lymphoma Cell Survival and Invasion

CC chemokine receptor 2 (CCR2) expression promotes diffuse large B-Cell lymphoma survival and invasion

Ccr1 Knockdown Suppresses Human Non-Small Cell Lung Cancer Cell Invasion

[CCL2 Protein Regulates Migration and Invasion of THP-1 Cells by Autosecreting Inflammatory Chemokines].

Involvement of a novel chemokine decoy receptor CCX-CKR in breast cancer growth, metastasis and patient survival.

Ribonucleotide reductase M2B inhibits cell migration and spreading by early growth response protein 1-mediated phosphatase and tensin homolog/Akt1 pathway in hepatocellular carcinoma.

Ccr7 Mediates Human Breast Cancer Cell Invasion, Migration by Inducing Epithelial-Mesenchymal Transition and Suppressing Apoptosis Through Akt Pathway

Increased Expression Of Ccrl2 Is Correlated With Clinical Prognosis In Human Bladder Cancer

CC Chemokine Ligand 21 Enhances the Immunogenicity of the Breast Cancer Cell Line MCF-7 Upon Assistance of TLR2.

Purification of recombinant human chemokine CCL2 in E. coli and its function in ovarian cancer

Elevated chemokine CC-motif receptor-like 2 (CCRL2) promotes cell migration and invasion in glioblastoma

CCL28 Promotes Breast Cancer Growth and Metastasis Through MAPK-mediated Cellular Anti-Apoptosis and Pro-Metastasis

CCL2/CCR2 signaling in cancer pathogenesis

Bioinformatics Approach to Identifying Potential Cancer-Associated Mutations in CCL2

Suppressed CCL2 expression inhibits the proliferation of leukemia cells via the cell cycle protein Cyclin D1: preliminary in vitro data.

Mccl21-A(1-57),a C-terminal Deletion Mutant of CCL21,Inhibits CCL21-mediated Migration in Cultured SW480 Cells by Suppressing ERK Activation

CRTC2 Promotes Non-Small Cell Lung Cancer A549 Migration and Invasion in Vitro.

Targeting the CCL2/CCR2 Axis in Cancer Immunotherapy: One Stone, Three Birds?

Role of the CCL2‐CCR2 signalling axis in cancer: Mechanisms and therapeutic targeting